Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Immunai
New York, New York, United States
- Ownership
- Private
- Employees
- ~80
- Development stage
- Other
01
Overview
Immunai is an AI-driven computational immunology company focused on accelerating therapeutic development for its partners. Its core platform, which includes AMICA (Annotated Multi-Omic Immune Cell Atlas)—the world's largest single-cell immune database—and the Immunodynamics Engine, is utilized by pharma companies to optimize drug discovery, clinical trial design, and patient selection. Immunai itself does not develop or announce its own clinical-stage therapeutics, but rather provides foundational immune insights.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculeMonoclonal antibodyBiologicCell therapyGene therapy
- Industry
- Drug Discovery Services
02
Partnerships
Beyond the preview
Go deeper on Immunai.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunai.